Results
1
-
10
of
121
<
1
2
3
...
12
13
>
Smit C; Arends J; Peters L; Cosin J; Chene G; Raben D; Rockstroh J; Montforte Ad; Dabis F; Zangerle R; Daikos G; Mussini C; Mallolas J; de Wit S; Zinkernagel A.
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
,
BMC infectious diseases
[PubMed: 26537918]
[DOI: 10.1186/s12879-015-1224-1]
Borghi V; Bisi L; Manzini L; Cossarizza A; Mussini C.
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
,
Infection
[PubMed: 23225268]
[DOI: 10.1007/s15010-012-0378-7]
Rasmussen TA; Tolstrup M; Melchjorsen J; Frederiksen CA; Nielsen US; Langdahl BL; ?stergaard L; Laursen AL.
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
,
BMC infectious diseases
[PubMed: 21970555]
[DOI: 10.1186/1471-2334-11-267]
Padilla S; Masi? M; Garc?a N; Jarrin I; Tormo C; Guti?rrez F.
Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
,
BMC infectious diseases
[PubMed: 21294867]
[DOI: 10.1186/1471-2334-11-40]
Galindo J; Amariles P; Mueses-Mar?n HF; Hincapi? JA; Gonz?lez-Avenda?o S; Galindo-Orrego X.
Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment na?ve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
,
BMC infectious diseases
[PubMed: 27716093]
[DOI: 10.1186/s12879-016-1871-x]
Adetokunboh OO; Schoonees A; Balogun TA; Wiysonge CS.
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis.
,
BMC infectious diseases
[PubMed: 26502899]
[DOI: 10.1186/s12879-015-1183-6]
Dorjee K; Baxi SM; Reingold AL; Hubbard A.
Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.
,
BMC infectious diseases
[DOI: 10.1186/s12879-017-2808-8]
Sabin CA; Reiss P; Ryom L; d'Arminio Monforte A; El-Sadr W; Lundgren JD; Phillips AN; Weber R; Law M; Fontas E; Mocroft A; de Wit S; Smith C; Dabis F.
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
,
BMC medicine
[DOI: 10.1186/s12916-016-0588-4]
Greig SL; Deeks ED.
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
,
Drugs
[DOI: 10.1007/s40265-015-0361-6]
Adetokunboh OO; Schoonees A; Wiysonge CS.
Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol.
,
Systematic reviews
[DOI: 10.1186/2046-4053-3-87]
<
1
2
3
...
12
13
>